PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'National Centre of Toxicology (CENATOX), 31 Ave. and 114 Street, Marianao, Havana, Cuba.\', \'Finlay Vaccine Institute. 21(st) Ave. N° 19810 between 198 and 200 Streets, Atabey, Playa, Havana, Cuba.\', \'Finlay Vaccine Institute. 21(st) Ave. N° 19810 between 198 and 200 Streets, Atabey, Playa, Havana, Cuba. Electronic address: ochoa@finlay.edu.cu.\', \'Institute of Cybernetics, Mathematics and Physics. 15 Street N° 551 between C and D Streets, Vedado, Havana, Cuba.\', \'Center of Molecular Immunology, 15(th) Ave. and 216 Street, Siboney, Playa, Havana, Cuba.\', \'Research Centre of Civil Defense, San José de las Lajas, Mayabeque, Cuba.\', \'National Coordinating Centre of Clinical Trials, 5(th) Ave. between 60 and 62 Ave., Miramar, Playa, Havana, Cuba.\', \'Chengdu Olisynn Biotech. Co. Ltd., and State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, People\'s Republic of China.\']
?:citedBy
  • -1
?:creator
?:doi
  • S0264-410X(22)00161-X10.1016/j.vaccine.2022.02.029
?:doi
?:hasPublicationType
?:journal
  • Vaccine
is ?:pmid of
?:pmid
?:pmid
  • 35164986
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.863
?:rankingScore_hIndex
  • 159
is ?:relation_isRelatedTo_publication of
?:title
  • A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity.
?:type
?:year
  • 2022

Metadata

Anon_0  
expand all